Enhancing CAR T Therapy in Pancreatic Cancer by Targeting Tumor-Supporting Cells

Pancreatic cancer remains one of the most formidable challenges in oncology, largely due to its diagnosis at advanced stages when surgical options are often exhausted. Among its variants, pancreatic ductal adenocarcinoma (PDAC) is the most common and notoriously resilient against conventional treatments. A significant barrier to effective therapy has been the dense desmoplastic stroma—a fibrotic meshwork comprising connective tissue, extracellular matrix proteins, and specialized cancer-associated fibroblasts (CAFs)—which not only physically impedes drug delivery but also fosters an immunosuppressive tumor microenvironment. This dual role of the stroma has critically limited the success of immunotherapeutic modalities, including the promising chimeric antigen receptor (CAR) T cell therapy that has shown remarkable efficacy in hematologic malignancies but falters in solid tumors.

Recent groundbreaking research led by Ellen Puré at the University of Pennsylvania’s School of Veterinary Medicine offers a revolutionary approach to overcoming this hurdle. Her team deployed lipid nanoparticles (LNPs)—nano-scale lipid-based vectors adept at delivering nucleic acids—directly to T cells within the body, effectively prompting these immune cells to express CARs that specifically target fibroblast activation protein (FAP). FAP is uniquely overexpressed on a subset of CAFs pivotal in maintaining the stromal architecture and promoting tumor progression in PDAC. This innovative method ushers in an era where T cells are “engineered” in vivo rather than ex vivo, bypassing complex laboratory manipulations and potentially reducing treatment cost and complexity.

Conventional CAR T cell therapy typically involves harvesting a patient’s T cells, genetically modifying them ex vivo to express a CAR that recognizes cancer-specific antigens, followed by reinfusion into the patient. This process necessitates extensive cell culture, quality control, and often requires preconditioning regimens such as lymphodepletion, which diminishes competing immune cells to create favorable conditions for CAR T cell engraftment. By contrast, LNP-mediated delivery of CAR mRNA allows direct programming of T cells inside the patient, drastically simplifying the procedure. Khuloud Bajbouj, a senior investigator in Puré’s lab, elucidates that these lipid-based vehicles serve as precise delivery “packages,” ensuring efficient transfer of CAR-encoding mRNA directly into T cells circulating in vivo.

The rationale for targeting FAP-positive CAFs stems from their contributory role in PDAC’s pathobiology. CAFs not only sustain the desmoplastic scaffold but also modulate immune cells, promoting an environment that protects tumors from immune attack. Prior experiments using traditional CAR T cells specific for FAP demonstrated reduced tumor growth, but these required cumbersome cell therapy protocols. The latest study reveals that a single administration of targeted LNPs (tLNPs) encoding FAP CAR mRNA yields superior or comparable tumor inhibition in preclinical PDAC models, compared to traditional approaches.

Remarkably, tLNP delivery achieves CAR expression on a significantly higher proportion of intratumoral T cells than conventional methods. Whereas traditional CAR T infusions arm approximately 10% of tumor-infiltrating T cells, the researchers observed 40 to 60% CAR positivity when using LNPs. This elevated arming effect translates into a robust and synchronous immune assault, described by Puré as an “entire army coming in all at once” instead of a staggered, wave-like infiltration typical of ex vivo engineered CAR T therapies. The transient nature of CAR expression induced by LNPs could also mitigate potential long-term toxicities associated with persistent CAR T cells.

Perhaps the most astonishing outcome of this strategy was the near-complete dissolution of the desmoplastic matrix within tumors. Targeting FAP-positive CAFs led not only to their depletion but also to the “melting away” of the fibrotic barrier itself, thereby potentially enhancing tumor accessibility to other therapeutic agents. This finding suggests a dual mechanism of action: directly attacking stromal cells to weaken tumor defenses, while simultaneously facilitating improved perfusion and immune infiltration.

Such stromal remodeling has far-reaching implications for the treatment of solid tumors broadly. Bajbouj notes that the tLNP approach could be synergistically combined with established treatments like chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates, potentially overcoming the longstanding challenge of stromal-mediated therapeutic resistance. Furthermore, the technique holds promise for rapid in vivo screening of novel CAR constructs or other gene therapies that have yet to demonstrate clinical efficacy, expanding the horizon for experimental oncology.

Metastasis, the primary cause of mortality in cancer patients, may also be amenable to this approach. FAP-positive CAFs assist malignant cells in detaching, surviving systemic circulation, and colonizing distant organs by preparing supportive microenvironments—analogous to gardeners preparing soil beds before planting. By eradicating these supportive stromal cells, the metastatic cascade may be disrupted, offering a novel intervention point to limit cancer spread and improve survival outcomes.

Beyond oncology, the versatility of tLNP-mediated CAR expression could extend to non-cancerous pathologies characterized by aberrant fibroblast activation and fibrosis. Conditions such as pulmonary fibrosis, autoimmune disorders, chronic arthritis, and abnormal wound healing might benefit from transient, targeted elimination of pathological fibroblast populations. Given the impracticality and risk profile of administering conventional CAR T therapies for these indications, the more transient and potentially safer mRNA-LNP modality emerges as a compelling alternative.

The translational potential of this technology is further underscored by the involvement of diverse collaborators spanning veterinary and human medicine, as well as biotechnology sectors, reflecting its multidisciplinary nature. Supported by funding agencies and biotechnology firms, this work exemplifies the convergence of nanotechnology, immunology, and gene therapy in crafting next-generation therapeutics. As the research progresses toward clinical trials, it holds promise not only for revolutionizing pancreatic cancer treatment but also for reshaping the future of immunotherapy against solid tumors and fibrotic diseases.

In sum, the innovative use of lipid nanoparticles to deliver CAR mRNA in vivo represents a paradigm shift in cancer immunotherapy. By effectively “melting away” the formidable stromal barrier in pancreatic tumors and enabling potent, transient CAR T cell responses, this approach addresses multiple limitations inherent to conventional CAR T cell therapy. It offers a streamlined, scalable, and potentially safer therapeutic strategy that could unlock new frontiers in treating some of the most deadly and refractory solid tumors.

News Publication Date: 17-Mar-2026

Web References: https://aacrjournals.org/cancerimmunolres/article-abstract/doi/10.1158/2326-6066.CIR-25-0663/774531/Targeted-Lipid-Nanoparticle-Delivery-of-FAP-CAR